Story thread · 6 reports / 5 sources
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
biopharmadive.com · 1d
How the coverage leans
Across 5 sources · syndicated copies counted once
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
First report: Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? — finance.yahoo.com, 4d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.